BiVictriX Therapeutics plc announced that Non-Executive Director, Iain Ross, is stepping down from the board with immediate effect to pursue other interests. A Nomination Committee, consisting of Non-Executive Directors and chaired by Dr. Michael Kauffman, will initiate a search for Iain's replacement with appropriate skills to help move the Company forward, in anticipation of its first clinical trials in patients with Acute Myeloid Leukaemia.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11 GBX | +10.00% | -4.35% | +4.76% |
04-17 | Bivictrix granted FDA orphan drug status for rare cancer treatment | AN |
04-17 | BiVictriX Wins US FDA's Orphan Drug Status for Blood Cancer Treatment | MT |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+4.76% | 10.48M | |
+44.48% | 54.04B | |
+43.57% | 41.96B | |
-0.86% | 41.92B | |
-7.59% | 28.35B | |
+12.30% | 26.35B | |
-21.83% | 19B | |
+7.15% | 13B | |
+29.40% | 12.28B | |
+25.15% | 12.19B |
- Stock Market
- Equities
- BVX Stock
- News BiVictriX Therapeutics Plc
- Bivictrix Therapeutics plc Announces Resignation of Iain Ross from the Board